Welcome to our dedicated page for Lyell Immunopharma SEC filings (Ticker: LYEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lyell Immunopharma, Inc. (Nasdaq: LYEL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Lyell is a late-stage clinical company developing next-generation CAR T-cell therapies for cancer, and its filings give structured insight into how it reports clinical, financial, and corporate developments.
Among the key documents are Current Reports on Form 8‑K, where Lyell furnishes press releases on quarterly financial results and business highlights, including updates on pivotal trials of rondecabtagene autoleucel (ronde‑cel/LYL314) in relapsed and/or refractory large B-cell lymphoma and progress in its broader CAR T-cell pipeline. Other 8‑K filings describe material agreements, such as the Exclusive License Agreement granting Lyell rights to the GCC‑targeted CAR T-cell product candidate LYL273, and a Securities Purchase Agreement for a private placement of common stock and potential pre‑funded warrants to fund pivotal-stage trials.
Filings also detail unregistered sales of equity securities related to private placements, milestone share issuances following an acquisition, and equity consideration under licensing arrangements. Additional 8‑K items cover changes in key officers, including appointments and resignations in financial leadership roles, providing context on corporate governance and management structure.
On Stock Titan, these filings are complemented by AI-powered tools that can help summarize lengthy documents, highlight items such as financing terms, licensing economics, and clinical milestone triggers, and surface relevant sections across multiple reports. Users interested in LYEL can review Forms 8‑K and other periodic reports as they become available to track how Lyell discloses clinical progress, capital structure changes, and significant agreements connected to its CAR T-cell programs.
Lyell Immunopharma, Inc. files a shelf registration to permit the resale by selling stockholders of 1,952,360 shares of common stock issued at a Milestone Closing. The registration is for resale only; Lyell will not receive proceeds from sales under this prospectus.
The prospectus states the shares were issued in a private placement and that Lyell paid registration expenses; it lists a March 6, 2026 Milestone Closing and discloses a last reported Nasdaq sale price of $21.21 per share as of April 2, 2026.
Lyell Immunopharma reported that Chief Financial and Business Officer Smital Shah received a grant of options to buy 140,000 shares of common stock. The options have a $25.50 exercise price and expire on March 8, 2036. Twenty-five percent will vest on March 9, 2027, with the rest vesting in equal monthly installments over the following 36 months, contingent on continued service.
Lyell Immunopharma, Inc. executive Smital Shah, the Chief Financial and Business Officer, has filed an initial Form 3 as an insider of the company. This filing establishes Shah as a reporting person under SEC rules and, in this instance, does not report any insider transactions.
Lyell Immunopharma, Inc. provides an overview of its business, risks and clinical pipeline as a late-stage cell therapy company focused on cancer. The company is developing next‑generation autologous CAR T-cell therapies aimed at more durable responses in hematologic malignancies and solid tumors.
Lead candidate rondecabtagene autoleucel (LYL314) is a dual‑targeting CD19/CD20 CAR T for large B‑cell lymphoma, now in a pivotal single‑arm 3L+ trial (PiNACLE) and a Phase 3 head‑to‑head 2L trial (PiNACLE‑H2H) versus axi‑cel or liso‑cel. Reported Phase 1/2 data showed high response rates with a safety profile described as appropriate for outpatient use.
LYL273, a GCC‑targeted CAR T for metastatic colorectal cancer licensed from ICT, achieved a 67% overall response rate and 83% disease control rate at the highest U.S. Phase 1 dose as of October 28, 2025, with cytokine‑release and gastrointestinal toxicities managed via protocol adjustments. The report also highlights proprietary anti‑exhaustion and manufacturing technologies, an in‑house LyFE manufacturing facility in Bothell, Washington, extensive competition, substantial ongoing losses, and the need for significant additional capital and successful regulatory approvals.
Lyell Immunopharma, Inc. reported a GAAP net loss of $140.7 million for Q4 2025 and $274.4 million for full year 2025, narrower than 2024. Non-GAAP net loss was $33.1 million for Q4 and $144.8 million for the year. Cash, cash equivalents and marketable securities were $247.2 million as of December 31, 2025, excluding a subsequent $50 million private placement tranche, which together are expected to fund operations into the second quarter of 2027.
Clinically, Lyell advanced ronde-cel, initiating patient dosing in the Phase 3 PiNACLE-H2H head‑to‑head CAR T trial in second‑line large B‑cell lymphoma and continuing the pivotal PiNACLE trial in later‑line disease. Updated Phase 1/2 ronde‑cel data showed high response rates and an outpatient‑appropriate safety profile.
For LYL273, a next‑generation GCC‑targeted CAR T for metastatic colorectal cancer, a U.S. Phase 1 trial is ongoing, with seven additional patients treated without dose‑limiting toxicity and encouraging dose‑dependent activity. Lyell also closed the second $50 million tranche of a $100 million equity private placement and appointed Smital Shah as Chief Financial and Business Officer.
ARCH Venture funds increased their indirect stake in Lyell Immunopharma, Inc. by purchasing 488,090 shares of common stock in an open-market transaction on March 6, 2026, at $25.61 per share. The filing attributes ownership to ARCH Venture Fund IX-affiliated limited partnerships, with the general partner and managing directors disclaiming beneficial ownership beyond their pecuniary interests.
Lyell Immunopharma, Inc. reported an insider purchase by ARCH Venture Fund XIII, L.P. On March 6, 2026, ARCH Venture Fund XIII, L.P. made an open-market purchase of 488,090 shares of Lyell common stock at $25.61 per share, held indirectly through ARCH-related entities.
Following this transaction, ARCH Venture Fund XIII, L.P. held 1,426,528 Lyell shares. The filing also lists indirect holdings of 910,317 shares each for other ARCH-managed funds. General partners and investment committee members may be deemed beneficial owners but disclaim beneficial ownership except to the extent of any pecuniary interest.
Lyell Immunopharma, Inc. appointed Smital Shah as its Chief Financial and Business Officer and principal financial officer, effective March 9, 2026, replacing the interim role previously held by CEO Lynn Seely, M.D.
Under her offer letter, Shah will receive an initial annual base salary of $500,000 and a target annual bonus of up to 50% of base salary. She will also be granted an option to purchase 140,000 shares of common stock at fair market value on the grant date, vesting 25% after one year and the remainder in equal monthly installments over the following three years, contingent on continued employment.
Shah joins the company with prior senior finance and business leadership experience at ProQR Therapeutics, Gilead Sciences, major investment banks and other biotech roles, and will participate as a Tier I Employee in the company’s Officer Severance Plan.
Lyell Immunopharma’s President and CEO, Lynn Seely, reported an open‑market sale of company stock. On February 11, 2026, she sold 7,455 shares of common stock at a weighted average price of $23.39 per share. According to the filing, these shares were automatically sold to satisfy tax withholding obligations arising from the settlement of performance-based vested restricted stock units, rather than a discretionary sale of investment holdings. After this transaction, Seely directly beneficially owned 74,266 shares of Lyell Immunopharma common stock.
Lyell Immunopharma's Chief Operating Officer Stephen J. Hill reported an open-market sale of 1,236 shares of common stock on February 11, 2026. The shares were automatically sold to cover tax withholding obligations from the settlement of performance-based vested restricted stock units.
The sale was executed at a weighted average price of $23.39 per share, with individual trade prices ranging from $23.3939 to $24.7850 per share. Following this transaction, Hill directly beneficially owns 17,795 shares of Lyell Immunopharma common stock.